NCT04112641View on ClinicalTrials.gov

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

June 28, 2026

Study Completion Date

July 1, 2026

Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
DRUG

Nicotinamide riboside

Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.

DRUG

Placebo capsules

Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.

Trial Locations (1)

52245

Donna Hammond, Iowa City

All Listed Sponsors
lead

Donna Hammond, PhD

OTHER